An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum.
Lalvani
A
A
Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, UK.
Aidoo
M
M
Allsopp
C E
CE
Plebanski
M
M
Whittle
H C
HC
Hill
A V
AV
D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D015195:Drug Design; D000939:Epitopes / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D017780:Malaria Vaccines / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control*; D010963:Plasmodium falciparum / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000953:Antigens, Protozoan; D000939:Epitopes; D006680:HLA Antigens; D017780:Malaria Vaccines